Head-to-head evidence
AZD8233 vs Tafolecimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
AZD8233
Developed by AstraZeneca
NCT03593785 · Phase 1 · completed
This is a randomized, placebo-controlled, single ascending-dose study, though blinding is limited to participants rather than the full study team. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Tafolecimab · Sintbilo
Marketed by Innovent Biologics
NCT04289285 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial enrolled 804 participants and met its primary endpoint: LDL cholesterol fell by roughly 57 to 65 percentage points more than placebo across both dosing regimens, a highly statistically significant result.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD8233's landscape · Tafolecimab's landscape